Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Inclusion Criteria:

1. Age ≥ 18；

2. ECOG performance status 0-1;

3. Life expectancy is not less than 12 weeks;

4. Dose escalation and PK expansion part: Subjects diagnosed with advanced solidmalignancies who are refractory to standard therapies or for which no standardtherapy exists；

5. Efficacy expansion part：Ovarian Cancer、Breast Cancer、Pancreatic Cancer、ProstateCancer or other cancer types with HRR gene mutation；

6. At least one target lesion (except maintenance therapy);

7. Adequate organ and marrow function as defined by the protocol.

Exclusion Criteria:

1. Surgery or chemotherapy within 4 weeks of the first dose of study treatment；

2. Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption；

3. Active HBV/HCV/HIV infection;

4. Untreated and/or uncontrolled brain metastases.